Kardigan, Inc.
KARD
Last
$14.67
Day
+3.3%
1y
-35.5%
5y
-35.5%
52w
-47.4%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1031d
EMA 21
15.67
EMA 50
17.80
EMA 200
20.58
20d high
-26.8%
5y high
-47.4%
5y range
13th
Positions held
Your positionsKARD isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-6
Hold
avoid
Signal
Sell
Target
$16.43
Stop
$12.34
Stop distance
15.9%
Target vs last
+12.0%
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
Bull case
- Kardigan, Inc. operates in the biotechnology sector, which is known for its potential to innovate and create groundbreaking therapies that can significantly improve patient outcomes.
- The company's market capitalization stands at approximately $1.26 billion, indicating a substantial valuation in the healthcare market.
- Kardigan has a strong buy recommendation, suggesting that analysts see potential for significant upside in the stock.
Bear case
- The company has reported negative net income for multiple quarters, with a net income of -116.236 million in Q2 2026.
- Kardigan's revenue has consistently been $0.0 over the past several quarters, indicating a lack of operational income.
- The stock has a strong sell signal with a score of -24.00, reflecting negative trends in technical indicators and market performance.
Fundamentals
| Market cap | $1.33B | Enterprise value | $743.50M | Trailing P/E | — | Forward P/E | -4.44 |
| PEG | — | Price / book | 2.16 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | 0.02 |
| Current ratio | 8.72 | Free cash flow | — | Analyst recommendation | strong_buy | Mean target | $42.25 |
| 52w high | $27.00 | 52w low | $12.23 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$116M | -$56.1M | -$57.4M | -$18.0M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$75.2M | -$58.7M | -$57.1M | -$26.1M |
Yearly (6y)
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0.0M | $0.0M |
| Op margin | — | — |
| Net income | -$192M | -$88.7M |
| Gross margin | — | — |
| Gross profit | — | — |
| Operating income | -$202M | -$96.7M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
2026-09-02 · Kardigan to Present at Two September Investor Conferences
2026-08-11 · Kardigan: Q2 Earnings Snapshot
2026-08-11 · Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
2026-07-31 · 2 ‘Strong Buy’ IPO Stocks JPMorgan Thinks Are Worth Watching
Price (daily)
Full chart · RSI · MACD · patternsKARD · daily-13.6% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin